亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

未开盘 05-07 16:00:00 EDT

21.70

+0.13

+0.60%

盘后21.70

+0.000.00%

16:10 EDT

最高22.37	最低21.70	成交量2,903
今开22.37	昨收21.57	日振幅3.12%
总市值20.25亿	流通市值15.53亿	总股本9,333万
成交额6.36万	换手率0.00%	流通股本7,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":21.7,"timestamp":1778184000000,"preClose":21.57,"halted":0,"volume":2903,"hourTrading":{"tag":"盘后","latestPrice":21.7,"preClose":21.7,"latestTime":"16:10 EDT","volume":3,"amount":65.46,"timestamp":1778184605101,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.006026889197960084,"floatShares":71582800,"shares":93330405,"eps":-1.995679,"marketStatus":"未开盘","change":0.13,"latestTime":"05-07 16:00:00 EDT","open":22.3723,"high":22.3723,"low":21.7,"amount":63560.885,"amplitude":0.031168,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.995679,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778227200000},"marketStatusCode":0,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":21.57,"postHourTrading":{"tag":"盘后","latestPrice":21.7,"preClose":21.7,"latestTime":"16:10 EDT","volume":3,"amount":65.46,"timestamp":1778184605101,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.483848},"requestUrl":"/m/hq/s/AAPG/tweets","defaultTab":"tweets","newsList":[{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630353293?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1032955483.USD","BK1161","LU0234570918.USD","BK4533","LU1244550577.SGD","LU0868494708.USD","LU2247934214.USD","IE00B42XCP33.USD","LU0823417653.USD","LU0348723411.USD","CSCL","BK4588","SG9999001424.SGD","LU0203345920.USD","LU1221951129.SGD","LU2237443622.USD","SG9999002224.SGD","LU2286300806.USD","CSCS","CSCO","LU0234572021.USD","LU0889566641.SGD","LU0203347892.USD","BK4020","BK4585","LU1066051498.USD","LU1162221912.USD","BK1574","06855","LU1674673691.USD","LU2237443895.HKD","LU1066051811.HKD","IE00BVYPNV92.GBP","IE000M9KFDE8.USD","LU1267930813.SGD","LU1778281490.HKD","LU2237443465.HKD","AAPG","SG9999015945.SGD","BK4579","LU1571399168.USD","LU2102340556.USD","SG9999015986.USD","LU1066053197.SGD","LU1883839398.USD","IE00BSNM7G36.USD","LU1059921491.USD","BK4560","LU0942090050.USD","IE00B3PB1722.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069553","title":"亚盛医药-B(06855)多项研究入选2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069553?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:05","pubTimestamp":1776812706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)公布，公司三个重点品种的六项临床研究入选2026年美国临床肿瘤学会(ASCO)年会，其中三项获快速口头报告，三项获壁报展示。这三个重点品种分别为中国首个获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(商品名：耐立克®)、中国首个获批上市的国产塬创Bcl-2选择性抑制剂利沙托克拉(商品名：利生妥®)和MDM2-p53抑制剂Alrizomadlin(APG-115)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","06855","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721474","title":"亚盛医药-B(06855)授出受限制股份单位及购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628721474?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:42","pubTimestamp":1776696140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，截至本公告日期，已向2022年受限制股份单位计划的3名选定人士授出69.63万份受限制股份单位，相当于 69.63万股股份，其中向本公司执行董事兼首席执行官杨大俊博士(杨博士)授出39.38万份受限制股份单位;向本公司首席医学官兼主要股东翟一帆博士(翟博士)授出28.39万份受限制股份单位;及向本公司1名高级管理人员授出1.86万份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","BK1574","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791678","title":"亚盛医药-B(06855)四项临床前进展亮相2026年美国癌症研究协会 (AACR)年会，展现多重联合治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628791678?lang=zh_cn&edition=full","pubTime":"2026-04-20 07:14","pubTimestamp":1776640456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 公布，公司将在2026年美国癌症研究协会年会上以壁报形式公布四项临床前研究成果。该会议于2026年4 月17日至2026年4月22日在美国加州圣地亚哥举行。本次壁报涉及公司三个品种，包括：原创1类新药BCR-ABL抑制剂奥雷巴替尼、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、以及PRC2/EED抑制剂APG-5918。此外，公司针对BRAF突变肿瘤开展的APG-2449 研究、以及针对小细胞肺癌开展的APG-5918研究，凸显了公司聚焦攻克耐药机制、探索联合用药策略的战略方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628208448","title":"光鲜销售下的深层危机：亚盛医药的盈利困局与三大致命风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2628208448","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628208448?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:01","pubTimestamp":1776423660,"startTime":"0","endTime":"0","summary":"在国产创新药赛道上，亚盛医药曾是最耀眼的明星之一。然而，其近日披露的2025年年报，却揭示了一家明星企业“销量猛增、亏损加剧”的典型困境。　　表面上看，核心产品耐立克销售额突破4.35亿元，整体商业化收入同比增长90%，似乎交出了一份不错的成绩单。但细究之下，公司全年净亏损高达12.43亿元，同比扩大206.4%，创下历史新高。这背后，隐藏着三大不可忽视的结构性风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-04-17/doc-inhuveqy6429410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627497821","title":"加速布局儿童实体瘤治疗领域！亚盛医药 MDM2-p53 抑制剂APG-115获CDE纳入\"星光计划\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2627497821","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627497821?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:14","pubTimestamp":1776140040,"startTime":"0","endTime":"0","summary":"此次APG-115获纳入\"星光计划\"，将有助于公司与CDE的进一步紧密沟通，获得儿童人群研究过程中技术问题的针对性指导。APG-115此次获纳入CDE'星光计划'，是国家药监机构对该品种临床价值与研发前景的高度认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK4129","LU1923622291.USD","BK4139","LU1223082519.USD","06855","APG","CDE","LU2125909916.SGD","LU1223082196.USD","LU2125909759.SGD","BK1574","BK4017","AAPG","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626338621","title":"两大血液瘤王牌爆卖5亿元难救主，亚盛医药又亏了12亿元，能否熬到创新药盈利拐点｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626338621","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626338621?lang=zh_cn&edition=full","pubTime":"2026-04-09 21:44","pubTimestamp":1775742264,"startTime":"0","endTime":"0","summary":"身披国产肿瘤原创新药领军者、细胞凋亡领域深耕者光环的创新药新贵亚盛医（06855.HK），近日披露的2025年年度报告无疑给市场扔下一枚深水炸弹，这份年报呈现了公司“产品销售猛增、整体业绩亏损”的矛盾反差。年报显示，亚盛医药的核心血液瘤产品矩阵表现亮眼，耐立克?（奥雷巴替尼）与利生妥?（利沙托克拉）合计实现销售收入5.06亿元，商业化收入同比大幅增长90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699953985.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699953985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","AAPG","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623574361","title":"亚盛医药2025年报：双引擎驱动下自我造血与全球创新加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2623574361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623574361?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:50","pubTimestamp":1774831800,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2025年，对于中国创新药企亚盛医药（NASDAQ：AAPG；HKEX：6855）而言，是一个从“研发驱动”向“商业化与研发双轮驱动”跨越的关键之年。公司最新公布的2025年全年业绩，不仅交出了一份亮眼的商业化成绩单，更清晰地勾勒出其“全球创新”战略迈入全新阶段的蓝图。财报显示，报告期内，公司总收入5.74亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688161756.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688161756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811719","title":"“十亿美元分子”双核共振，亚盛医药-B(06855)加速全球创新价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811719?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:49","pubTimestamp":1774583348,"startTime":"0","endTime":"0","summary":"3月26日，亚盛医药-B2025年年度业绩正式出炉。“十亿美元分子”双核共振，夯实创新与全球化根基作为一家已经进入商业化加速阶段的创新药企业，亚盛医药在2025年最核心的价值研判锚点在于：不同于此前依靠耐立克“单点突破”，公司现阶段的全球商业化已步入“十亿美元分子”双核共振关键期。作为亚盛医药的第二款商业化产品，利生妥报告期内获批上市，为公司“十亿美元分子”双核共振奠定了重要基础，也成为公司业绩加速增长的关键一极。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06855","AAPG","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811531","title":"【券商聚焦】中信建投证券维持亚盛医药(06855)“买入”评级 基于商业化产品放量及国际化管线潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811531?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:17","pubTimestamp":1774581463,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，亚盛医药 2025年业绩符合预期，核心投资论点基于其商业化产品放量及国际化管线潜力。报告认为，公司核心产品奥雷巴替尼营收实现大幅增长，利沙托克拉商业化前景优异，且两款产品的多个全球三期临床持续推动，构成未来增长动力。另一产品利沙托克拉在上市后五个月实现销售收入7058万元。基于商业化放量及管线潜力，维持对亚盛医药-B的“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622788916","title":"亚盛医药-B(06855)2025年股东亏损同比扩大206.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622788916","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622788916?lang=zh_cn&edition=full","pubTime":"2026-03-26 08:46","pubTimestamp":1774485965,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)公告公布，截至2025年12月31日止年度，母公司拥有人应占亏损12.43亿元(人民币，下同)，同比亏损扩大206.53%；每股基本亏损3.49元。期内，集团收入5.74亿元，同比减少41.46%。耐立克（奥雷巴替尼）销售额同比增长81%至4.35亿元。期内，集团研发开支11.37亿元，同比增长20.08%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4139","06855","AAPG","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622588314","title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622588314?lang=zh_cn&edition=full","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK4139","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620041734","title":"亚盛医药-B(06855)将在2026年美国癌症研究协会年会上公布四项最新临床前进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620041734?lang=zh_cn&edition=full","pubTime":"2026-03-18 08:17","pubTimestamp":1773793027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司共有四项临床前研究进展入选2026年美国癌症研究协会年会。此次会议将于2026年4月17日至 2026年4月22日在美国加州圣地亚哥举行。从群体科学与预防，到癌症生物学、转化医学与临床研究，再到幸存者关怀与权益倡导，AACR年会全方位展示了前沿的癌症科学与医学成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","06855","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611705143","title":"亚盛医药盘中异动 股价大涨6.42%报24.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611705143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611705143?lang=zh_cn&edition=full","pubTime":"2026-02-14 05:00","pubTimestamp":1771016411,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日05时00分，亚盛医药股票出现波动，股价大幅上涨6.42%。截至发稿，该股报24.69美元/股，成交量4603股，换手率0.00%，振幅2.31%。亚盛医药股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，Moolec Science Sa、Aim Immunotech Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为6877.68%、357.46%、298.52%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Aim Immunotech Inc.，振幅分别为174.71%、80.59%、75.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","ASPHF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611359651","title":"亚盛医药盘中异动 股价大跌5.65%报23.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611359651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611359651?lang=zh_cn&edition=full","pubTime":"2026-02-13 04:56","pubTimestamp":1770929785,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日04时56分，亚盛医药股票出现异动，股价快速下挫5.65%。截至发稿，该股报23.21美元/股，成交量1257股，换手率0.00%，振幅3.17%。最近的财报数据显示，该股实现营业收入32.21百万美元，净利润-81.43百万美元，每股收益-0.95美元，毛利23.92百万美元，市盈率-11.45倍。亚盛医药股票所在的生物技术行业中，整体涨幅为0.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","AAPG","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609095558","title":"亚盛医药BTK降解剂APG-3288新药临床申请（IND）获CDE许可，全球临床开发再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609095558?lang=zh_cn&edition=full","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CDE","BK4129","LU2125909916.SGD","BK1574","06855","BK4017","IND","APG","AAPG","LU1223083913.SGD","BK1161","BK4144","BK4139","LU1923622291.USD","LU1223082519.USD","TK","LU1223082196.USD","LU2125909759.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608335305","title":"亚盛医药-B盘中涨超3% BTK降解剂1类新药APG-3288片获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335305","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335305?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:08","pubTimestamp":1770174480,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B盘中涨超3%，截至发稿，股价上涨1.38%，报45.88港元，成交额3697.50万港元。公开资料显示，这是亚盛医药研发的新一代BTK靶向蛋白降解疗法。　　APG-3288是亚盛医药自主研发的首个新型高效和高选择性BTK降解剂。临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-04/doc-inhkrihn3096297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2125909759.SGD","LU1923622291.USD","BK1574","BK4129","BK4139","LU2125909916.SGD","AAPG","06855","BK1161","APG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","BK1574","BK1191","02269","AAPG","01477","06855","06978","BK1161","02268","01530","ZLAB","09688","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601828013","title":"港股异动 | 亚盛医药-B(06855)涨近4% BTK降解剂APG-3288新药临床申请获美国FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828013","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601828013?lang=zh_cn&edition=full","pubTime":"2026-01-07 10:39","pubTimestamp":1767753579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)涨近4%，截至发稿，涨3.69%，报53.4港元，成交额6164.18万港元。消息面上，1月7日，亚盛医药官微消息，公司宣布，原创新一代BTK靶向蛋白降解剂 APG-3288的新药临床申请(IND)已获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。这标志着公司在靶向蛋白降解领域的研发成果正式进入临床阶段，是亚盛医药全球创新管线的又一重大布局。该研究是一项全球多中心、开放性的I期临床研究，旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","APG","BK1574","LU1923622291.USD","LU2125909759.SGD","BK4139","AAPG","LU2125909916.SGD","BK1161","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595713529","title":"亚盛医药-B(06855)：David Sidransky将获委任为首席独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713529","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595713529?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:47","pubTimestamp":1767106065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，Debra Yu博士将获委任为董事会提名委员会新增成员，自2025年12月26日起生效。David Sidransky博士将获委任为首席独立非执行董事，自2025年12月26日起生效，以作为其他董事与本公司股东之间的中间人;及在与董事会主席或本公司管理层的正常沟通渠道不足的情况下，可与其他董事及本公司股东联络。研发委员会将由Marc E. Lippman, MD博士担任主席，由David Sidransky博士及王少萌博士担任成员。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK4139","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0514},{"period":"1month","weight":-0.206},{"period":"3month","weight":-0.115},{"period":"6month","weight":-0.3161},{"period":"1year","weight":-0.1021},{"period":"ytd","weight":-0.173}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤治疗药物发现、研发及商业化的控股公司。该公司主营业务是从事开发及销售针对肿瘤、乙肝及老化相关的疾病的新型小规模疗法。该公司的主要产品包括Olverembatinib（HQP1351）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918等产品。该公司的产品主要用于治疗主要血液系统恶性肿瘤，包括慢性粒细胞白血病、急性粒细胞白血病、慢性淋巴细胞白血病、急性淋巴细胞白血病、骨髓增生异常综合症及多发性骨髓瘤。该公司主要在国内市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}